Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
filingDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_405850e9e168a528a140a056dcc4ad38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_370d00e7177ccc1380b1f90121d77bd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f347c1c21caa065933ee802b2d1d7d4a |
publicationDate |
2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-201904576-A |
titleOfInvention |
Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
abstract |
The present invention provides a method for treating and / or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, which comprises administering an effective amount of 7- to a patient with HCC characterized by HBV infection (6- (2-hydroxyprop-2-yl) pyridin-3-yl) -1-(( trans ) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3 -b ] pyrazine-2 ( 1H ) -one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as "Compound 1"). |
priorityDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |